Skip to main content
Top
Published in: Discover Oncology 1/2021

Open Access 01-12-2021 | Endoscopy | Research

Endoscopy biopsy is not efficiency enough for diagnosis of mucinous colorectal adenocarcinoma

Authors: Shuai Xiao, Jia Huang, Yiwei Zhang, Rong Tang, Yunhua Xu, Rongfang He, Qiulin Huang, Jun Ouyang, Xuyu Zu, Xiuda Peng, Kai Fu

Published in: Discover Oncology | Issue 1/2021

Login to get access

Abstract

Background

Endoscopy biopsy (EB) is the standard diagnostic method for colorectal cancer (CRC), whereas its accuracy and efficiency in mucinous adenocarcinoma (MAC) initial diagnosis is unclear.

Methods

The initial EB and postoperative specimen (PS) pathological diagnosis of MAC from two centers were retrospectively collected and analyzed. The accuracy and efficiency of initial EB compared with PS pathological diagnosis were analyzed. The potential factors which would affect the initial EB diagnosis of MAC were analyzed.

Results

280 and 78 eligible cases were enrolled in this study from two centers respectively. The initial EB diagnosis accuracy for MAC were 84.62% and 83.33%. However, among the cases of PS diagnosis with MAC, the diagnostic efficiency of initial EB was only 36.49% and 32.50% respectively. Lower tumor differentiation and more EB number were associated with an increased probability for the EB diagnosis of MAC, but only tumor differentiation was an independent diagnositic factor for EB in the two cohorts.

Conclusions

The accuracy of initial EB with MAC is high, but the diagnostic efficiency was extremely low. Tumor differentiation and EB number were associated with the diagnosis efficiency of MAC before surgery.
Appendix
Available only for authorised users
Literature
1.
go back to reference Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–32.CrossRef Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–32.CrossRef
2.
go back to reference Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet (London, England). 2019;394(10207):1467–80.CrossRef Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet (London, England). 2019;394(10207):1467–80.CrossRef
3.
go back to reference Hugen N, Brown G, Glynne-Jones R, de Wilt JH, Nagtegaal ID. Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2016;13(6):361–9.CrossRef Hugen N, Brown G, Glynne-Jones R, de Wilt JH, Nagtegaal ID. Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol. 2016;13(6):361–9.CrossRef
4.
go back to reference Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019;39(1):13.CrossRef Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019;39(1):13.CrossRef
5.
go back to reference Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, et al. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Br J Cancer. 2013;108(10):1978–84.CrossRef Lee DW, Han SW, Lee HJ, Rhee YY, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, et al. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. Br J Cancer. 2013;108(10):1978–84.CrossRef
6.
go back to reference Hugen N, Verhoeven RH, Radema SA, de Hingh IH, Pruijt JF, Nagtegaal ID, Lemmens VE, de Wilt JH. Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. Ann Oncol. 2013;24(11):2819–24.CrossRef Hugen N, Verhoeven RH, Radema SA, de Hingh IH, Pruijt JF, Nagtegaal ID, Lemmens VE, de Wilt JH. Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. Ann Oncol. 2013;24(11):2819–24.CrossRef
7.
go back to reference Mekenkamp LJ, Heesterbeek KJ, Koopman M, Tol J, Teerenstra S, Venderbosch S, Punt CJ, Nagtegaal ID. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48(4):501–9.CrossRef Mekenkamp LJ, Heesterbeek KJ, Koopman M, Tol J, Teerenstra S, Venderbosch S, Punt CJ, Nagtegaal ID. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48(4):501–9.CrossRef
8.
go back to reference Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005;16(8):1305–10.CrossRef Negri FV, Wotherspoon A, Cunningham D, Norman AR, Chong G, Ross PJ. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005;16(8):1305–10.CrossRef
9.
go back to reference Miyakita H, Sadahiro S, Ogimi T, Saito G, Okada K, Tanaka A, Suzuki T, Kajiwara H, Yamamuro H, Akiba T. Mucinous components assessed by magnetic resonance imaging in primary rectal cancer tissue before and after chemoradiotherapy and tumor response. Int J Colorectal Dis. 2018;33(8):1135–8.CrossRef Miyakita H, Sadahiro S, Ogimi T, Saito G, Okada K, Tanaka A, Suzuki T, Kajiwara H, Yamamuro H, Akiba T. Mucinous components assessed by magnetic resonance imaging in primary rectal cancer tissue before and after chemoradiotherapy and tumor response. Int J Colorectal Dis. 2018;33(8):1135–8.CrossRef
10.
go back to reference Yu SK, Chand M, Tait DM, Brown G. Magnetic resonance imaging defined mucinous rectal carcinoma is an independent imaging biomarker for poor prognosis and poor response to preoperative chemoradiotherapy. Eur J Cancer. 2014;50(5):920–7.CrossRef Yu SK, Chand M, Tait DM, Brown G. Magnetic resonance imaging defined mucinous rectal carcinoma is an independent imaging biomarker for poor prognosis and poor response to preoperative chemoradiotherapy. Eur J Cancer. 2014;50(5):920–7.CrossRef
11.
go back to reference Sharaf RN, Shergill AK, Odze RD, Krinsky ML, Fukami N, Jain R, Appalaneni V, Anderson MA, Ben-Menachem T, Chandrasekhara V, et al. Endoscopic mucosal tissue sampling. Gastrointest Endosc. 2013;78(2):216–24.CrossRef Sharaf RN, Shergill AK, Odze RD, Krinsky ML, Fukami N, Jain R, Appalaneni V, Anderson MA, Ben-Menachem T, Chandrasekhara V, et al. Endoscopic mucosal tissue sampling. Gastrointest Endosc. 2013;78(2):216–24.CrossRef
12.
go back to reference Rosati G, Galli F, Cantore M, Bergamo F, Banzi M, Zampino MG, Mattioli R, Cardellino GG, Ronzoni M, Di Bartolomeo M, et al. Predictive impact of mucinous tumors on the clinical outcome in patients with poorly differentiated, stage II Colon Cancer: A TOSCA Subgroup Analysis. Oncologist. 2020;8:9. Rosati G, Galli F, Cantore M, Bergamo F, Banzi M, Zampino MG, Mattioli R, Cardellino GG, Ronzoni M, Di Bartolomeo M, et al. Predictive impact of mucinous tumors on the clinical outcome in patients with poorly differentiated, stage II Colon Cancer: A TOSCA Subgroup Analysis. Oncologist. 2020;8:9.
13.
go back to reference Younes M, Katikaneni PR, Lechago J. The value of the preoperative mucosal biopsy in the diagnosis of colorectal mucinous adenocarcinoma. Cancer-Am Cancer Soc. 1993;72(12):3588–92. Younes M, Katikaneni PR, Lechago J. The value of the preoperative mucosal biopsy in the diagnosis of colorectal mucinous adenocarcinoma. Cancer-Am Cancer Soc. 1993;72(12):3588–92.
14.
go back to reference Kang CM, Lim SB, Hong SM, Yu CS, Hong YS, Kim TW, Park JH, Kim JH, Kim JC. Prevalence and clinical significance of cellular and acellular mucin in patients with locally advanced mucinous rectal cancer who underwent preoperative chemoradiotherapy followed by radical surgery. Colorectal Dis. 2016;18(1):O10–6.CrossRef Kang CM, Lim SB, Hong SM, Yu CS, Hong YS, Kim TW, Park JH, Kim JH, Kim JC. Prevalence and clinical significance of cellular and acellular mucin in patients with locally advanced mucinous rectal cancer who underwent preoperative chemoradiotherapy followed by radical surgery. Colorectal Dis. 2016;18(1):O10–6.CrossRef
15.
go back to reference Macken E, Moreels T, Vannoote J, Siersema PD, Van Cutsem E. Quality assurance in colonoscopy for colorectal cancer diagnosis. Eur J Surg Oncol (EJSO). 2011;37(1):10–5.CrossRef Macken E, Moreels T, Vannoote J, Siersema PD, Van Cutsem E. Quality assurance in colonoscopy for colorectal cancer diagnosis. Eur J Surg Oncol (EJSO). 2011;37(1):10–5.CrossRef
16.
go back to reference Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12(11):1071–80.CrossRef Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12(11):1071–80.CrossRef
17.
go back to reference Kim MJ, Park JS, Park SI, Kim NK, Kim JH, Moon HJ, Park YN, Kim WH. Accuracy in differentiation of mucinous and nonmucinous rectal carcinoma on MR imaging. J Comput Assist Tomogr. 2003;27(1):48–55.CrossRef Kim MJ, Park JS, Park SI, Kim NK, Kim JH, Moon HJ, Park YN, Kim WH. Accuracy in differentiation of mucinous and nonmucinous rectal carcinoma on MR imaging. J Comput Assist Tomogr. 2003;27(1):48–55.CrossRef
Metadata
Title
Endoscopy biopsy is not efficiency enough for diagnosis of mucinous colorectal adenocarcinoma
Authors
Shuai Xiao
Jia Huang
Yiwei Zhang
Rong Tang
Yunhua Xu
Rongfang He
Qiulin Huang
Jun Ouyang
Xuyu Zu
Xiuda Peng
Kai Fu
Publication date
01-12-2021
Publisher
Springer US
Published in
Discover Oncology / Issue 1/2021
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-021-00443-4

Other articles of this Issue 1/2021

Discover Oncology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine